Table 3. Prognostic factors on survival outcomes of 594 NPC patients by use of univariate analysis.

Characteristics	LRRFS (%)	P	DMFS (%)	P	PFS (%)	P	OS (%)	P
Sex		0.832		0.088		0.263		0.050
Male	89.3		89.1		84.0		91.7
Female	89.1		94.6		87.5		96.7
Age		0.164		0.824		0.737		0.061
<60	89.7		91.0		85.0		94.2
≥60	86.9		90.2		85.8		88.5
T stage		0.851		0.937		0.686		0.948
T1-T2	89.6		91.1		84.0		93.0
T3-T4	89.2		90.9		85.4		93.8
N stage		0.192		0.001		0.012		0.008
N0-N1	92.0		97.3		91.0		97.7
N2-N3	88.4		88.0		82.5		91.3
Clinical stage		0.111		0.004		0.016		0.008
III	90.5		93.5		87.3		95.6
IVA/B	87.2		86.4		81.4		89.4
AC		0.225		0.735		0.707		0.330
Yes	88.0		90.4		84.6		96.2
No	91.6		91.6		86.1		92.7
NAC regimen		0.450		0.850		0.662		0.945
TPF	88.2		91.6		83.9		93.6
TP	91.7		91.2		87.5		92.5
GP	93.8		91.8		89.8		95.9
FP	86.2		88.5		82.6		92.7
NAC cycle		0.149		0.043		0.037		0.266
2 cycles	91.3		93.3		88.7		94.0
3 to 4 cycles	87.2		88.5		81.7		92.6

LRRFS, locoregional relapse-free survival; DMFS, distant metastases-free survival; PFS, progression-free survival; OS, overall survival; AC, adjuvant chemotherapy; NAC, neoadjuvant chemotherapy; TP, docetaxel/cisplatin; TPF, docetaxel/cisplatin/fluorouracil; GP, gemcitabine/cisplatin; FP, cisplatin/fluorouracil.